Spineway (ALSPW) H2 2024 earnings summary

Executive summary

• Annual revenue reached €12 million in 2024, up 14% year-over-year, driven by organic growth and successful acquisitions of Distimp and Spine Innovations.

• Operating loss reduced to €0.9 million from €4.5 million in 2023, reflecting improved cost control and higher sales.

• Net loss narrowed to €3.9 million from €6.5 million in 2023; adjusted net loss (excluding Negma exceptional expense) was €2.4 million.

• Strategic investments in regulatory and clinical areas continued to support future growth and international expansion.

Financial highlights

• Gross margin held steady at 69% of revenue, supported by effective purchasing management.

• Net operating expenses fell 22% year-over-year, with personnel and running costs down 14% and 28%, respectively.

• Financial expenses increased to €2.5 million, including a €1.5 million exceptional charge from the Negma financing agreement.

• Cash position at year-end was €4.5 million, with net cash of €2.7 million after debt.

Outlook and guidance

• In-house ESP prosthesis production line expected to be operational in H1 2025, aiming to improve agility and margins.

• Plans to intensify marketing and regulatory investments to expand international presence and access new markets.

• Focus on maintaining organic growth and regaining sustainable profitability in the medium term.